Optimapharm organises and manages clinical trials for US and Western European pharmaceutical companies, biotech players and medical device companies. With the investment, Optimapharm will seek to continue to grow both organically and through strategic acquisitions.
The multijurisdictional deal required input from a number of foreign counsels focusing predominantly on Austria, Croatia, Czech Republic, Serbia and Switzerland.
The deal required expertise drawn from across the firm's private equity, banking and finance and tax teams.